Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): Riccardo Panella Added: 2 years ago
ECO 2024 — Dr Riccardo Panella (Aalborg University, DK) joins us to discuss a ncRNA-based approach in treating obesity. This new combinatory treatment (Resalis) aims to increase GLP1-RA efficacy by targeting non-coding RNA.Questions1. What is the background of this combinatory approach?2. What data did you present at ERA 24?3. What are the challenges and opportunities in approaching combinatory… View more
Added: 1 month ago Source:  Arrhythmia and Electrophysiology Review
Conduction system pacing has emerged as a potential alternative to conventional biventricular pacing (BiVP) for delivering cardiac resynchronization therapy (CRT). The recent LEFT-BUNDLE-CRT trial aimed to determine if left-bundle branch area pacing (LBBAP) is non-inferior to BiVP in patients with guideline-based indications for CRT and left-bundle branch block (LBBB).¹MethodologyThe LEFT-BUNDLE… View more
Author(s): Rui Yi Pang Added: 4 months ago
Journal of Asian Pacific Society of Cardiology 2026;5:e07. View more
Added: 2 months ago Source:  Interventional Cardiology Review Journal
For patients with atrial fibrillation (AF) at high risk for both stroke and bleeding, catheter-based left atrial appendage closure (LAAC) was not found to be non-inferior to physician-directed best medical care, according to the results of the CLOSURE-AF trial.¹MethodologyThe multicentre, randomised CLOSURE-AF trial was conducted in Germany to assess the effectiveness of LAAC compared with best… View more
Author(s): Milind Y Desai Added: 9 months ago
ESC Congress 2025 - ODYSSEY-HCM finds no improvements in patients with non-obstructive cardiomyopathy when treated with mavacamten.Dr Milind Desai (Cleveland Clinic, US) joins us to discuss findings from the ODYSSEY-HCM trial, evaluating the safety, tolerability, and efficacy of mavacamten in patients with symptomatic non-obstructive hypertrophic cardiomyopathy.The ODYSSEY-HCM study was a… View more
Author(s): Johann Bauersachs Added: 1 year ago
ESC HF 25 - SCD-PROTECT shows high risk of sudden cardiac arrest (SCA) and sudden cardiac death (SCD) during early medical therapy optimization for reduced LVEF in patients with new non-ischemic cardiomyopathy or MI/CAD.Prof Johann Bauersachs (Hannover Medical School, Hannover, DE) discusses findings from the SCD–PROTECT study, an investigation of sudden cardiac arrest in patients with newly… View more